BMYMP News and Press, Bristol-Myers Squibb $2Pr From 03/07/23

2023-03-07 14:07:10 ET Start Time: 09:50 End Time: 10:22 Bristol-Myers Squibb Company (BMY) Cowen 43rd Annual Healthcare Conference March 07, 2023, 09:50 AM ET Company Participants Samit Hirawat - EVP, Chief Medical Officer, and Drug Development Conference ...

2023-03-06 23:01:05 ET Summary Kahn Brothers’ 13F portfolio value increased from ~$642M to ~$760M this quarter. Most of the stakes saw minor adjustments during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~49% o...

2023-03-06 03:11:42 ET Summary In Q4 2022, the company's revenue was $24.29 billion, up 1.9% from the last three months of 2021, despite a significant decrease in people's desire to vaccinate against COVID-19. According to the Wall Street Journal, Pfizer's management is in talks t...

Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended December 31, 2022, Baron Health Care Fund rose 9.08% (Institutional Shares) vs. the 11.54% gai...

Summary Viatris' gross margin reached its highest level since its inception in the fourth quarter of 2020, despite rising raw material and labor costs. On February 27, 2023, Viatris management will publish financial results for the 4th quarter of 2022. Viatris' operating income for ...

Summary Bristol-Myers Squibb's revenue was $11,406 million in Q4 2022, showing mixed results compared to previous quarters, and there are many explanations for this, which will be discussed in the article. In 2023, the company's investors should receive a dividend of $2.28 per share, up...

Summary It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. Several drugmakers are expected to begin offering biosimilar ver...

Summary Anda's revenue generated $450 million for the company in the last three months of 2022, up $95 million from Q4 2022, driven by substantially increased demand for the company's services. Teva's European segment profit was $1,496 million in 2022, slightly up year-over-year, even t...

Summary Primary endpoint met with interim analysis released from phase 1b/2 FELIX study using obe-cel for the treatment of patients with relapsed/refractory Acute Lymphoblastic Leukemia; 70% Overall Remission Rate achieved. Recently released positive interim analysis results with obe-ce...

Summary Given enough time, stock in pharmaceutical giants has yielded life-altering gains. Because of its popular and widely distributed COVID-19 vaccine, Pfizer has sparked more controversy than other stocks in its sector. Eli Lilly has been one of the most exceptionally profitable...